1.43%
1.43%
-7.81%
-55.71%
-21.71%
-78.73%
-59.11%
AI Spotlight on ITOS
Company Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.Iteos Therapeutics, Inc.
was founded in 2011 and is headquartered in Watertown, Massachusetts.
Market Data
| Last Price | 7.79 |
| Change Percentage | 1.43% |
| Open | 7.73 |
| Previous Close | 7.68 |
| Market Cap ( Millions) | 285 |
| Volume | 71490 |
| Year High | 18.75 |
| Year Low | 7.09 |
| M A 50 | 7.88 |
| M A 200 | 12.28 |
Financial Ratios
| FCF Yield | -42.28% |
| Dividend Yield | 0.00% |
| ROE | -20.11% |
| Debt / Equity | 0.88% |
| Net Debt / EBIDTA | 85.17% |
| Price To Book | 0.53 |
| Price Earnings Ratio | -2.77 |
| Price To FCF | -2.37 |
| Price To sales | 12.01 |
| EV / EBITDA | -1.2 |
News
- Jan -13 - All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
- Dec -18 - iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
- Dec -12 - iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Nov -26 - iTeos to Participate in Upcoming Investor Conferences
- Nov -12 - iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Sep -16 - Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
- Sep -16 - iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- Sep -15 - iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
- Sep -14 - iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- Aug -28 - iTeos to Participate in Upcoming Investor Conferences
- Aug -20 - iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
- Aug -08 - ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
- Aug -05 - iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
- Jul -09 - iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
- Jul -08 - iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
- Jun -17 - iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
- May -10 - iTeos Therapeutics to raise $120 million via registered direct offering
- May -10 - iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- May -10 - iTeos Therapeutics Announces $120 Million Registered Direct Offering
- Apr -07 - iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cancer Immunotherapies
Expected Growth : 11.3 %
What the company do ?
iTeos Therapeutics, Inc.'s Cancer Immunotherapies are novel treatments that harness the power of the immune system to fight cancer, enhancing anti-tumor responses and improving patient outcomes.
Why we expect these perspectives ?
iTeos Therapeutics, Inc.'s Cancer Immunotherapies segment growth of 11.3% is driven by increasing adoption of novel checkpoint inhibitors, rising incidence of cancer, and growing demand for targeted therapies. Additionally, advancements in biomarker development, expansion into new indications, and strategic partnerships are contributing to the segment's rapid growth.
Iteos Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| EOS-448 | A potent and selective adenosine A2A receptor antagonist for the treatment of solid tumors |
| EOS-811 | A potent and selective anti-TIGIT antibody for the treatment of solid tumors |
| EOS-610 | A potent and selective A2B receptor antagonist for the treatment of solid tumors |
| EOS-942 | A potent and selective anti-PD-1 antibody for the treatment of solid tumors |
iTeos Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
iTeos Therapeutics, Inc. operates in a highly competitive industry with many substitutes available, but the company's focus on innovative cancer therapies and its strong research and development capabilities help to mitigate the threat of substitutes.
Bargaining Power Of Customers
iTeos Therapeutics, Inc. has a diverse customer base, and no single customer has significant bargaining power, reducing the company's dependence on individual customers.
Bargaining Power Of Suppliers
iTeos Therapeutics, Inc. relies on a few key suppliers for raw materials and services, but the company's strong relationships with suppliers and its ability to negotiate favorable terms help to mitigate the bargaining power of suppliers.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to iTeos Therapeutics, Inc.'s market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and iTeos Therapeutics, Inc. faces intense rivalry from established companies and new entrants, which can lead to pricing pressures and reduced market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.04% |
| Debt Cost | 3.95% |
| Equity Weight | 98.96% |
| Equity Cost | 10.29% |
| WACC | 10.22% |
| Leverage | 1.05% |
iTeos Therapeutics, Inc. : Quality Control
iTeos Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
